JD5037
JD5037 is a peripherally restricted cannabinoid-1 receptor (CB1R) inverse agonist. It is a novel compound that has been studied for its potential therapeutic applications in various medical conditions, including obesity, metabolic syndrome, and liver diseases.
Pharmacology
JD5037 is a peripherally restricted CB1R inverse agonist. This means it binds to the CB1R and induces a response opposite to that of an agonist. It does not cross the blood-brain barrier, which limits its effects to peripheral tissues. This is a significant advantage over other CB1R inverse agonists, as it reduces the risk of central nervous system side effects.
Therapeutic Applications
Obesity
JD5037 has been studied for its potential use in the treatment of obesity. It has been shown to reduce food intake and body weight in diet-induced obese mice. This is thought to be due to its ability to enhance leptin sensitivity and reduce lipogenesis in peripheral tissues.
Metabolic Syndrome
JD5037 may also have potential in the treatment of metabolic syndrome. Studies have shown that it can improve insulin sensitivity, reduce hyperglycemia, and decrease triglyceride levels in diet-induced obese mice.
Liver Diseases
The potential therapeutic applications of JD5037 extend to liver diseases as well. It has been shown to reduce liver inflammation and fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
Safety and Tolerability
JD5037 has been found to be well-tolerated in preclinical studies. Its peripheral restriction reduces the risk of central nervous system side effects, which have been a concern with other CB1R inverse agonists.
Future Directions
Further research is needed to fully understand the therapeutic potential of JD5037. This includes clinical trials in humans to assess its safety and efficacy in the treatment of obesity, metabolic syndrome, and liver diseases.
See Also
References
<references group="" responsive="1"></references>
Ad. Transform your life with W8MD's Budget GLP-1 injections from $75


W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $75 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
